Inferior vena cava filter placement and risk of hematogenous distant metastasis in ovarian cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 4, 2013, Pages 362-367

  Matsuo, Koji ^a   Carter, Charelle M ^b   Ahn, Edward H ^c   Prather, Chrisitina P ^d   Eno, Michele L ^e   Im, Dwight D ^f   Rosenshein, Neil B ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f MERCY MEDICAL CENTER   (United States)

Author keywords

distant metastasis; inferior vena cava filter; ovarian cancer; survival; venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DISTANT METASTASIS; FEMALE; HUMAN; INFERIOR CAVA VEIN; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PERITONEUM CANCER; SPLEEN METASTASIS; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

AGED; ANALYSIS OF VARIANCE; CAUSALITY; COHORT STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; DATABASES, FACTUAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; ODDS RATIO; OVARIAN NEOPLASMS; OVARIECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SPLENIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENA CAVA FILTERS; VENOUS THROMBOSIS;

EID: 84881022679     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318248da32     Document Type: Article

References (24)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
2. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374:1371-1382.
3. Gerestein CG, Damhuis RA, Burger CW, et al. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review. Gynecol Oncol. 2009;114:523-527.
4. Scarvelis D, Anderson J, Davis L, et al. Hospital mortality due to pulmonary embolism and an evaluation of the usefulness of preventative interventions. Thromb Res. 2010;125: 166-170.
5. Streiff MB. Diagnosis and initial treatment of venous throm-boembolism in patients with cancer. J Clin Oncol. 2009;27: 4889-4894.
6. Lee AY. Treatment of venous thromboembolism in cancer patients. Best Pract Res Clin Haematol. 2009;22:93-101.
7. Carrier M, Lee AY. Prophylactic and therapeutic anticoagulation for thrombosis: major issues in oncology. Nat Clin Pract Oncol. 2009;6:74-84.
8. Wallace MJ, Jean JL, Gupta S, et al. Use of inferior vena caval filters and survival in patients with malignancy. Cancer. 2004;101: 1902-1907.
9. Barginear MF, Lesser M, Akerman ML, et al. Need for inferior vena cava filters in cancer patients: a surrogate marker for poor outcome. Clin Appl Thromb Hemost. 2009;15: 263-269.
10. Schunn C, Schunn GB, Hobbs G, et al. Inferior vena cava filter placement in late-stage cancer. Vasc Endovascular Surg. 2006;40: 287-294.
11. Young T, Aukes J, Hughes R, et al. Vena caval filters for the prevention of pulmonary embolism. Cochrane Database Syst Rev. 2007;18:CD006212.
12. Raman R, Leming PD, Bhandari M, et al. Inferior vena cava filters in the management of cancer-associated venous thromboembo-lism: a systematic review. Oncol Rev. 2010;4:147-157.
13. Ihnat DM, Mills JL, Hughes JD, et al. Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine? J Vasc Surg. 1998;28: 800-807.
14. Dewdney SB, Benn T, Rimel BJ, et al. Inferior vena cava filter placement in the gynecologic oncology patient: a 15-year institutional experience. Gynecol Oncol. 2011;121:344-346.
15. Matsuo K, Bond VK, Eno ML, et al. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. Int J Cancer. 2009;125:2721-2727.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
17. Bose D, Leineweber K, Konorza T, et al. Release of TNF-alpha during stent implantation into saphenous vein aortocoronary bypass grafts and its relation to plaque extrusion and restenosis. Am J Physiol Heart Circ Physiol. 2007;292:H2295-H2299.
18. Sanchez-Margalet V, Cubero JM, Martin-Romero C, et al. Inflammatory response to coronary stent implantation in patients with unstable angina. Clin Chem Lab Med. 2002;40:769-774.
19. Bast RC Jr, Boyer CM, Jacobs I, et al. Cell growth regulation in epithelial ovarian cancer. Cancer. 1993;71(4 suppl):1597-1601.
20. Rath KS, Funk HM, Bowling MC, et al. Expression of soluble interleukin-6 receptor in malignant ovarian tissue. Am J Obstet Gynecol. 2010;203:230, e1-e8.
21. Poruk KE, Firpo MA, Huerter LM, et al. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2010;19:2605-2610.
22. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
23. Rickles FR. Cancer and thrombosis in women-molecular mechanisms. Thromb Res. 2009;123(suppl 2):S16-S20.
24. Thodiyil P, Kakkar AK. Can low-molecular-weight heparins improve outcome in patients with cancer? Cancer Treat Rev. 2002;28:151-155.